Apollo Hospitals Q1 FY27: Profit up 38%, margin 15.5%

Strong start to FY27 for Apollo Hospitals

Apollo Hospitals Enterprise Ltd reported a sharp year-on-year improvement in its first-quarter FY27 performance, led by higher revenue and operating profit. The results were disclosed on Wednesday, August 12, for the quarter ended June 30, 2026. The company also highlighted operational expansion during the quarter, including the launch of a new hospital in Bengaluru.

Alongside the earnings, the broader update pack referenced planned structural changes around Apollo HealthCo and upcoming shareholder agenda items. Apollo Hospitals’ stock, however, ended lower on the day of the results, indicating that the market reaction was not fully aligned with the headline growth.

Q1 FY27 consolidated results: profit, revenue and EBITDA

Apollo Hospitals reported consolidated net profit of ₹610 crore in Q1 FY27, up 38.4% from ₹441 crore in Q1 FY26. Consolidated revenue rose 20.6% year-on-year to ₹7,044 crore, compared with ₹5,842 crore a year ago. EBITDA increased 28.2% to ₹1,092 crore from ₹852 crore.

The EBITDA margin improved to 15.5% from 14.6% in the year-ago quarter. These figures point to faster growth in operating profit than in revenue, supporting the margin expansion.

The provided information also contained another reported consolidated PAT figure of ₹581 crore with a 34% year-on-year increase, alongside revenue cited at ₹7,043 crore. Separately, a version of the same metrics appeared with an extra digit (for example, revenue at ₹70,435 crore and PAT at ₹5,805 crore), which conflicts with the ₹7,044 crore revenue and ₹610 crore profit set. This article retains the figures as stated in the results summary while flagging the inconsistencies present in the supplied material.

Margin expansion signals operating leverage

The year-on-year rise in EBITDA margin to 15.5% from 14.6% suggests Apollo Hospitals saw improved operating leverage in Q1 FY27. EBITDA growth of 28.2% outpaced revenue growth of 20.6% on the consolidated base, aligning with the reported margin improvement.

While the summary does not break out cost drivers, the margin movement is an important marker for investors tracking whether growth is being achieved with stable or improving profitability. Apollo’s reported margin expansion also sets the baseline for market expectations ahead of the next quarters.

Healthcare services business: revenue and profitability

Apollo Hospitals’ healthcare services revenue increased 22% year-on-year to ₹3,567 crore in Q1 FY27, up from ₹2,935 crore in Q1 FY26. Segment EBITDA rose 20% to ₹862 crore from ₹718 crore. The segment EBITDA margin was reported at 24%.

Profit after tax for this healthcare services business was stated at ₹480 crore, up 25% from ₹384 crore. These figures indicate that the core healthcare services vertical continued to be the key earnings engine during the quarter.

New capacity: Sarjapur hospital launch in Bengaluru

During Q1 FY27, Apollo Hospitals launched its 180-bed hospital in Sarjapur, Bengaluru. The launch adds to the company’s physical network and is relevant in the context of its longer-term capacity expansion plans.

A separate business update in the supplied text stated Apollo Hospitals plans to add more than 5,800 new beds over the next five years. While the earnings summary does not provide capex or commissioning timelines beyond the Sarjapur facility, the bed-addition plan frames the company’s medium-term growth approach.

Management commentary provided with the results

Dr Prathap C. Reddy, Founder and Chairman, Apollo Hospitals Group, said Q1 FY27 marks a strong start to the year and that it builds on the momentum of FY26. The statement, as provided, reinforces management’s positioning of the quarter as a continuation of prior-year execution.

The compilation also referenced strategic themes such as AI integration and expansion, but without detailed quantitative disclosures in the same excerpt. As a result, the key verifiable takeaways remain the reported financial results and the disclosed operational launch.

Corporate actions: auditor appointment and proposed internal transaction

Apollo Hospitals approved the appointment of Price Waterhouse Chartered Accountants LLP as statutory auditors for the next five years, as stated in the provided text.

In addition, the group is considering a proposal to transfer Apollo HealthCo’s procurement and wholesale distribution undertaking to Apollo Consumer Products Limited through a slump sale. The expected completion date mentioned for this deal is October 1, 2026.

HealthCo demerger roadmap and profitability targets

The supplied material also referenced a plan to demerge and list the HealthCo arm by Q4 FY27. The same update cited a target of ₹25,000 crore in annualised revenue for Apollo HealthCo by Q4 FY27, along with an exit EBITDA margin guidance of 6.5% to 7% by fiscal year-end 2027.

It further stated that the Apollo 24/7 digital platform expects cash breakeven by Q1 FY27, and full breakeven (including ESOP costs) by Q3 FY27. The update also referenced an NCLT order dated May 5, 2026, and noted a mandatory shareholder meeting held on June 24, 2026, in relation to the demerger process.

Stock reaction and trading levels cited

Shares of Apollo Hospitals Enterprise Ltd ended at ₹8,565.00, down ₹186.00 or 2.13% on the BSE, as per the provided closing data. Another market snapshot in the supplied text cited “Today: 8,503.90”, and a separate line mentioned a current price of ₹8,945 and market capitalisation of ₹1,28,615 crore. These figures indicate that multiple price points were included in the information pack, likely reflecting updates at different times.

For investors, the key point is that the immediate post-results reaction cited was negative on the BSE close, despite strong year-on-year growth in the headline numbers.

Key numbers and dates at a glance

Why the update matters for investors

Apollo Hospitals’ Q1 FY27 results show a combination of strong growth and improved consolidated profitability, with EBITDA and margins expanding faster than revenue. The healthcare services business delivered robust growth in revenue, EBITDA, and PAT, underscoring the strength of the core hospital-led model.

At the same time, the broader set of disclosed actions points to ongoing corporate restructuring and governance items, including the statutory auditor appointment, a potential internal slump sale transaction, and the stated timeline for the HealthCo demerger and listing by Q4 FY27. Investors will likely track progress on these milestones, along with any clarity management provides during the August 13 conference call and at the August 25 AGM.

Conclusion

Apollo Hospitals entered FY27 with higher revenue, stronger operating profit, and an improved EBITDA margin in Q1, alongside a new 180-bed hospital launch in Bengaluru. The next key checkpoints in the company’s calendar are the August 13 investor call and the August 25 AGM, where corporate agenda items and forward milestones may draw attention.